Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.
Elderly
Heart failure
The Length of hospital stay
Tolvaptan
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
29 04 2022
29 04 2022
Historique:
received:
29
06
2021
accepted:
19
04
2022
entrez:
29
4
2022
pubmed:
30
4
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Elderly patients with heart failure (HF) have been observed to decrease activities of daily living (ADL) during hospitalization. Prevention of ADL decline from shortening of hospital stays is especially important in the elderly, because decreasing ADL is associated with poor prognosis. We investigated the relationship between the early initiation of tolvaptan (TLV) after hospitalization and the length of hospital stay in patients with HF aged younger than 80 years and aged 80 years and older. We analyzed 146 patients younger than 80 years (< 80) and 101 patients aged 80 years and older (≥ 80) who were hospitalized with HF from February 2011 to June 2016 and had initiated TLV. The relationship between the time until commencement of TLV and the length of hospital stay was assessed. Additionally, a comparison made between the TLV early start group (within the median) and the delayed start group (over the median) for both groups. Multivariate analysis was also performed on factors that required hospital stays below the median. A significant correlation was observed between time to TLV initiation and the length of hospital stay (< 80: r = 0.382, P < 0.001; ≥ 80: r = 0.395, P < 0.001). The length of hospital stay in the early group was significantly longer than that in the delayed group for both groups (< 80: early 21.0 ± 13.0 days and 33.0 ± 22.7 days, respectively, P < 0.001; ≥ 80: early 21.3 ± 12.5 days and 32.9 ± 17.9 days, respectively, P < 0.001). Conversely, no statistically significant difference found in the length of hospital stay after initiation of TLV. Moreover, no increase in adverse events in the elderly observed. A multivariate analysis revealed that a predictive factor for short-term hospitalization was early administration of TLV regardless of age. The early initiation of TLV after hospitalization was associated with a shorter length of hospital stay in patients with HF regardless of age.
Sections du résumé
BACKGROUND
Elderly patients with heart failure (HF) have been observed to decrease activities of daily living (ADL) during hospitalization. Prevention of ADL decline from shortening of hospital stays is especially important in the elderly, because decreasing ADL is associated with poor prognosis. We investigated the relationship between the early initiation of tolvaptan (TLV) after hospitalization and the length of hospital stay in patients with HF aged younger than 80 years and aged 80 years and older.
METHODS
We analyzed 146 patients younger than 80 years (< 80) and 101 patients aged 80 years and older (≥ 80) who were hospitalized with HF from February 2011 to June 2016 and had initiated TLV. The relationship between the time until commencement of TLV and the length of hospital stay was assessed. Additionally, a comparison made between the TLV early start group (within the median) and the delayed start group (over the median) for both groups. Multivariate analysis was also performed on factors that required hospital stays below the median.
RESULTS
A significant correlation was observed between time to TLV initiation and the length of hospital stay (< 80: r = 0.382, P < 0.001; ≥ 80: r = 0.395, P < 0.001). The length of hospital stay in the early group was significantly longer than that in the delayed group for both groups (< 80: early 21.0 ± 13.0 days and 33.0 ± 22.7 days, respectively, P < 0.001; ≥ 80: early 21.3 ± 12.5 days and 32.9 ± 17.9 days, respectively, P < 0.001). Conversely, no statistically significant difference found in the length of hospital stay after initiation of TLV. Moreover, no increase in adverse events in the elderly observed. A multivariate analysis revealed that a predictive factor for short-term hospitalization was early administration of TLV regardless of age.
CONCLUSIONS
The early initiation of TLV after hospitalization was associated with a shorter length of hospital stay in patients with HF regardless of age.
Identifiants
pubmed: 35488212
doi: 10.1186/s12872-022-02640-7
pii: 10.1186/s12872-022-02640-7
pmc: PMC9052442
doi:
Substances chimiques
Antidiuretic Hormone Receptor Antagonists
0
Tolvaptan
21G72T1950
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Informations de copyright
© 2022. The Author(s).
Références
Heart Vessels. 2018 Feb;33(2):145-154
pubmed: 28815407
Arch Gerontol Geriatr. 2017 Nov;73:269-278
pubmed: 28869885
Circ Rep. 2019 Sep 26;1(10):431-437
pubmed: 33693080
Intern Med. 2019 Feb 15;58(4):471-475
pubmed: 30210135
ESC Heart Fail. 2021 Feb;8(1):527-538
pubmed: 33185011
Circ J. 2008 Mar;72(3):489-91
pubmed: 18296852
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Int Heart J. 2018 Nov 28;59(6):1368-1377
pubmed: 30369583
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Circ J. 2019 Jun 25;83(7):1520-1527
pubmed: 31118355
Int J Cardiol. 2017 May 15;235:162-168
pubmed: 28259550
Circ J. 2011;75(10):2403-10
pubmed: 21778592
Crit Care Med. 2008 Jan;36(1 Suppl):S129-39
pubmed: 18158472
Int Heart J. 2018 Jan 27;59(1):120-125
pubmed: 29269711
J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67
pubmed: 2698218
Circ J. 2009 Oct;73(10):1893-900
pubmed: 19644216
Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S33-45
pubmed: 22120092
Anatol J Cardiol. 2017 Sep;18(3):206-212
pubmed: 28777097
J Am Heart Assoc. 2018 Sep 18;7(18):e008687
pubmed: 30371201
Heart Vessels. 2018 Apr;33(4):367-373
pubmed: 29128961
Circ J. 2018 Apr 25;82(5):1344-1350
pubmed: 29607892
Int J Cardiol. 2011 Oct 6;152(1):88-94
pubmed: 21397348
Circ J. 2014;78(9):2259-67
pubmed: 25008779
Circ J. 2018 Oct 25;82(11):2793-2799
pubmed: 30158344
Circ Rep. 2020 Jul 7;2(8):393-399
pubmed: 33693260
Eur J Heart Fail. 2007 Oct;9(10):1064-9
pubmed: 17719273
J Cardiol. 2020 Oct;76(4):342-349
pubmed: 32636125
Heart Vessels. 2019 Apr;34(4):607-615
pubmed: 30386917
Circ J. 2019 Sep 25;83(10):2084-2184
pubmed: 31511439